Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer
Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, two-arm, multicenter Phase IA/II dose-escalation study of PTK787 in
combination with Pemetrexed alone (Cohort 1) or Pemetrexed and Cisplatin (Cohort 2).
This study is designed to determine the maximum tolerated dose (MTD) and dose limiting
toxicity (DLT) of PTK787 when administered in combination with Pemetrexed or Pemetrexed and
Cisplatin, and to characterize the safety, tolerability, biologic activity, and PK profile of
PTK787 in adult patients with advanced non-small cell lung cancers and mesotheliomas.